Home > Boards > US OTC > Medical - Healthcare > Medizone Intl. (MZEIQ)

BenK: You obviously have not done your

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
fcmboca Member Profile
Followed By 0
Posts 59
Boards Moderated 0
Alias Born 05/08/18
160x600 placeholder
fcmboca   Saturday, 05/18/19 01:07:33 PM
Re: BenK post# 49318
Post # of 49380 

BenK: You obviously have not done your homework and research. Dodd was one of the founders of GeoVax back in 2011 and has been on the Board of Directors since then. He was named the CEO after the tragic moves by the scammers "the Marshalls". Check out the report below about the progress of the research done by GeoVax. MZEI and the Marshalls never even got to this point. The only thing they accomplished is scamming all the investors (including you) out of big bucks over many years,

ATLANTA, GA, May 15, 2019 – GeoVax Labs, Inc. (OTCQB: GOVXD), a biotechnology company developing human vaccines, announced that it will deliver a presentation showcasing the Company’s unique technology during the Innovative Vaccines Against Resistant Infectious Diseases and Emerging Threats Conference, presented by the Microbiology and Infectious Diseases Discussion Group of The New York Academy of Sciences. The conference is being held May 20, 2019 in New York, New York. GeoVax’s presentation is entitled “Development of Single-Dose Vaccines for Emerging Infectious Diseases Using a Novel Plug and Play Live Viral Vector Platform, Preclinical Data for Zika, Ebola and Lassa Fever Vaccines as Examples.”

The poster presentation will be delivered by Michael Hellerstein, GeoVax’s Director of Regulatory Affairs and Quality Systems, and will feature GeoVax’s “Plug and Play” vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated. The MVA-VLP platform has several advantages including the ability to use single inoculations to achieve full protection. Single-dose protection is a favorable characteristic of a vaccine for emerging infectious disease outbreak response, given the speed of spread of pathogens and the impracticality of multi-dose regimens in the under-resourced settings where outbreaks often occurs. In studies for Ebola, Lassa and Zika, representing important human pathogens from 3 different virus families, a single dose of GeoVax’s vaccine fully protected animals against a lethal challenge. These serve as examples of the broad utility of the MVA-VLP platform for many more indications. GeoVax’s MVA platform has previously been shown to elicit both durable antibody and T cell responses against HIV in several clinical trials.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

GeoVax’s current development programs are focused on preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and multiple cancers. The Company has designed the leading preventative HIV vaccine candidate to fight against the subtype of HIV prevalent in the larger commercial markets of the Americas, Western Europe, Japan, and Australia; this program is currently undergoing human clinical trials managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV. For more information, visit www.geovax.com.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist